TISIDB

Summary
Symbol	UBE2K
Name	ubiquitin-conjugating enzyme E2K
Aliases	HYPG; UBC1; HIP2; huntingtin interacting protein 2; ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast); ......
Chromosomal Location	4p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm
Domain	PF00627 UBA/TS-N domain PF00179 Ubiquitin-conjugating enzyme
Function	Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro, in the presence or in the absence of BRCA1-BARD1 E3 ubiquitin-protein ligase complex, catalyzes the synthesis of 'Lys-48'-linked polyubiquitin chains. Does not transfer ubiquitin directly to but elongates monoubiquitinated substrate protein. Mediates the selective degradation of short-lived and abnormal proteins, such as the endoplasmic reticulum-associated degradation (ERAD) of misfolded lumenal proteins. Ubiquitinates huntingtin. May mediate foam cell formation by the suppression of apoptosis of lipid-bearing macrophages through ubiquitination and subsequence degradation of p53/TP53. Proposed to be involved in ubiquitination and proteolytic processing of NF-kappa-B; in vitro supports ubiquitination of NFKB1. In case of infection by cytomegaloviruses may be involved in the US11-dependent degradation of MHC class I heavy chains following their export from the ER to the cytosol. In case of viral infections may be involved in the HPV E7 protein-dependent degradation of RB1.

> Gene Ontology [ TOP ]
Biological Process	GO:0000209 protein polyubiquitination GO:0001959 regulation of cytokine-mediated signaling pathway GO:0001961 positive regulation of cytokine-mediated signaling pathway GO:0009894 regulation of catabolic process GO:0010498 proteasomal protein catabolic process GO:0010799 regulation of peptidyl-threonine phosphorylation GO:0010800 positive regulation of peptidyl-threonine phosphorylation GO:0010993 regulation of ubiquitin homeostasis GO:0010994 free ubiquitin chain polymerization GO:0018107 peptidyl-threonine phosphorylation GO:0018210 peptidyl-threonine modification GO:0031329 regulation of cellular catabolic process GO:0031349 positive regulation of defense response GO:0032434 regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032844 regulation of homeostatic process GO:0034340 response to type I interferon GO:0034976 response to endoplasmic reticulum stress GO:0035456 response to interferon-beta GO:0035458 cellular response to interferon-beta GO:0042176 regulation of protein catabolic process GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0051258 protein polymerization GO:0060337 type I interferon signaling pathway GO:0060338 regulation of type I interferon-mediated signaling pathway GO:0060340 positive regulation of type I interferon-mediated signaling pathway GO:0060759 regulation of response to cytokine stimulus GO:0060760 positive regulation of response to cytokine stimulus GO:0061136 regulation of proteasomal protein catabolic process GO:0070059 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress GO:0070936 protein K48-linked ubiquitination GO:0071357 cellular response to type I interferon GO:0097193 intrinsic apoptotic signaling pathway GO:1903050 regulation of proteolysis involved in cellular protein catabolic process GO:1903362 regulation of cellular protein catabolic process
Molecular Function	GO:0004842 ubiquitin-protein transferase activity GO:0019787 ubiquitin-like protein transferase activity GO:0031625 ubiquitin protein ligase binding GO:0034450 ubiquitin-ubiquitin ligase activity GO:0044389 ubiquitin-like protein ligase binding GO:0061630 ubiquitin protein ligase activity GO:0061659 ubiquitin-like protein ligase activity
Cellular Component	GO:0030175 filopodium GO:0032433 filopodium tip GO:0098858 actin-based cell projection

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04120 Ubiquitin mediated proteolysis
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-983168: Antigen processing R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-392499: Metabolism of proteins R-HSA-936440: Negative regulators of RIG-I/MDA5 signaling R-HSA-597592: Post-translational protein modification R-HSA-8852135: Protein ubiquitination R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways R-HSA-8866652: Synthesis of active ubiquitin

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04120 Ubiquitin mediated proteolysis

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-983168: Antigen processing
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-936440: Negative regulators of RIG-I/MDA5 signaling
R-HSA-597592: Post-translational protein modification
R-HSA-8852135: Protein ubiquitination
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-8866652: Synthesis of active ubiquitin

Summary
Symbol	UBE2K
Name	ubiquitin-conjugating enzyme E2K
Aliases	HYPG; UBC1; HIP2; huntingtin interacting protein 2; ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast); ......
Chromosomal Location	4p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between UBE2K and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	UBE2K
Name	ubiquitin-conjugating enzyme E2K
Aliases	HYPG; UBC1; HIP2; huntingtin interacting protein 2; ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast); ......
Chromosomal Location	4p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of UBE2K in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.32; FDR: 0.04180	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.54	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	UBE2K
Name	ubiquitin-conjugating enzyme E2K
Aliases	HYPG; UBC1; HIP2; huntingtin interacting protein 2; ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast); ......
Chromosomal Location	4p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of UBE2K in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.136	0.562
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.076	0.97
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.185	0.897
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.159	0.678
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.235	0.885
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.656	0.742
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.109	0.8
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.028	0.988
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.188	0.928
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.72	0.618
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.973	0.674
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.09	0.1

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of UBE2K in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	UBE2K
Name	ubiquitin-conjugating enzyme E2K
Aliases	HYPG; UBC1; HIP2; huntingtin interacting protein 2; ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast); ......
Chromosomal Location	4p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UBE2K. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	UBE2K
Name	ubiquitin-conjugating enzyme E2K
Aliases	HYPG; UBC1; HIP2; huntingtin interacting protein 2; ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast); ......
Chromosomal Location	4p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UBE2K. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UBE2K. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	UBE2K
Name	ubiquitin-conjugating enzyme E2K
Aliases	HYPG; UBC1; HIP2; huntingtin interacting protein 2; ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast); ......
Chromosomal Location	4p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UBE2K. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	UBE2K
Name	ubiquitin-conjugating enzyme E2K
Aliases	HYPG; UBC1; HIP2; huntingtin interacting protein 2; ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast); ......
Chromosomal Location	4p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of UBE2K expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	UBE2K
Name	ubiquitin-conjugating enzyme E2K
Aliases	HYPG; UBC1; HIP2; huntingtin interacting protein 2; ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast); ......
Chromosomal Location	4p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between UBE2K and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	UBE2K
Name	ubiquitin-conjugating enzyme E2K
Aliases	HYPG; UBC1; HIP2; huntingtin interacting protein 2; ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast); ......
Chromosomal Location	4p14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting UBE2K collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse UBE2K